[go: up one dir, main page]

WO2015183985A3 - Therapeutic compositions including naphthoquinones and uses thereof - Google Patents

Therapeutic compositions including naphthoquinones and uses thereof Download PDF

Info

Publication number
WO2015183985A3
WO2015183985A3 PCT/US2015/032716 US2015032716W WO2015183985A3 WO 2015183985 A3 WO2015183985 A3 WO 2015183985A3 US 2015032716 W US2015032716 W US 2015032716W WO 2015183985 A3 WO2015183985 A3 WO 2015183985A3
Authority
WO
WIPO (PCT)
Prior art keywords
naphthoquinones
phe
lys
arg
aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/032716
Other languages
French (fr)
Other versions
WO2015183985A2 (en
Inventor
D. Travis Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stealth Peptides International Inc
Original Assignee
Stealth Peptides International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides International Inc filed Critical Stealth Peptides International Inc
Publication of WO2015183985A2 publication Critical patent/WO2015183985A2/en
Publication of WO2015183985A3 publication Critical patent/WO2015183985A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of naphthoquinones, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to naphthoquinones and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2',6'-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2',6'-Dmt-Lys-Phe-NH2.
PCT/US2015/032716 2014-05-28 2015-05-27 Therapeutic compositions including naphthoquinones and uses thereof Ceased WO2015183985A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462003741P 2014-05-28 2014-05-28
US62/003,741 2014-05-28

Publications (2)

Publication Number Publication Date
WO2015183985A2 WO2015183985A2 (en) 2015-12-03
WO2015183985A3 true WO2015183985A3 (en) 2016-03-17

Family

ID=54700045

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/032716 Ceased WO2015183985A2 (en) 2014-05-28 2015-05-27 Therapeutic compositions including naphthoquinones and uses thereof

Country Status (1)

Country Link
WO (1) WO2015183985A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2625740C1 (en) * 2016-10-10 2017-07-18 Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) Means for treating ischemia of vascular brains
CN115364221A (en) * 2022-07-11 2022-11-22 海南医学院第一附属医院 Application of up-regulation expression promoter of Apelin/APJ pathway in medicine for treating renal injury caused by paraquat poisoning
CN115326958B (en) * 2022-08-11 2023-11-24 北京大学第三医院（北京大学第三临床医学院） A marker composition to assist in predicting or diagnosing obese children with hyperlipidemia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303436A1 (en) * 2012-12-06 2013-11-14 Stealth Peptides Internatioanl, Inc. Peptide therapeutics and methods for using same
WO2014022551A1 (en) * 2012-08-02 2014-02-06 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014022551A1 (en) * 2012-08-02 2014-02-06 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
US20130303436A1 (en) * 2012-12-06 2013-11-14 Stealth Peptides Internatioanl, Inc. Peptide therapeutics and methods for using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KATRITZKY, AR ET AL.: "Efficient Syntheses Of Naphthoquinone-Dipeptides.", SYNTHESIS., vol. 12, 2010, pages 2011 - 2016 *

Also Published As

Publication number Publication date
WO2015183985A2 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
WO2016004093A3 (en) Therapeutic compositions including galectin-3 inhibitors and uses thereof
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
HK1215934A1 (en) Peptide therapeutics and methods for using same
WO2015183995A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
WO2014205317A3 (en) Cyclic peptides as protein targeting agents
WO2014165607A3 (en) Aromatic-cationic peptide formulations, compositions and methods of use
HK1249011A1 (en) Therapeutic compositions including mitochondrial fission inhibitor peptides, variants thereof and methods of using the same
HK1198869A1 (en) Combination treatments for hepatitis c
MX2017004592A (en) Pharmaceutical formulations for the oral delivery of peptide or protein drugs.
PH12015502002A1 (en) Tripeptide epoxy ketone protease inhibitors
MY199967A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
CY1119007T1 (en) COMPOSITIONS AND METHODS OF Pulmonary Hypertension Treatment
JO3326B1 (en) Tripeptide Epoxy Ketone Protease Inhibitors
WO2015171965A3 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
SA519410993B1 (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
WO2015183984A3 (en) Therapeutic compositions including tocopherol and uses thereof
MX389088B (en) METHODS FOR TREATING HCV.
MX2022013450A (en) Pharmaceutical formulations.
WO2016015798A9 (en) Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population
WO2015183985A3 (en) Therapeutic compositions including naphthoquinones and uses thereof
MX2020007062A (en) Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof.
EP4219534A3 (en) Methods for treatment of and prophylaxis against inflammatory disorders
NZ719321A (en) Storage stable lyophilized tripeptide formulations
MX2016012722A (en) Methods for treating hcv.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15800451

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 15800451

Country of ref document: EP

Kind code of ref document: A2